Imvax
PrivateLast Round
VC Round
Jan 29, 2025
Total Funding Raised
$175M
Company Overview
Imvax is a biotechnology company that develops patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other solid tumor cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Imvax Comparables
Compare Imvax with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AiVita Biomedical | 83% | |
| IN8bio | 81% | |
| Diakonos Oncology | 81% | |
Imvax Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jan 29, 2025 | ||||
| VC Round | May 21, 2024 | ||||
| Series C Extension | Sep 6, 2023 | ||||
| Series C | Jul 16, 2020 | ||||
| Series B | May 1, 2019 | ||||
Series A | Jun 16, 2017 |
Imvax Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Benjamin Franklin Technology Partners | Series A |
| Magnetar Capital | Series C |
| Thomas Jefferson University | Series A |
| Invus Opportunities | Series C |
| TLP Investment Partners | Series C |
| TLP Invest | Series C |
| Ziff Capital Partners | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 29, 2025
$29M round completed.
- Sep 6, 2023
Raised $23M Series C Extension round
Imvax Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Imvax's valuation, stock price, and market status.